Marcus Bosenberg, MD, PhD

• Adebowale Adeniran
• Akiko Iwasaki
• Curtis Jamison Perry
• David Calderwood
• David F. Stern
• David Rimm
• Donald Engelman
• Goran Micevic
• Harriet Kluger
• Jonathan Leventhal
• Kim Blenman
• Koonam Park
• Michael Girardi
• Noel Turner
• Peter M. Glazer
• Richard Flavell
• Ruth Halaban
• Samir Amin
• Sarah Weiss
• Sateja Paradkar
• Thuy Tran
• Vish Muthusamy
• William Damsky
• Yuval Kluger

Cell Biology; Dermatology; Melanoma; Neoplasm Metastasis; Pathology

• 34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedemaBelzer A, Bosenberg M, Leventhal J. 34811 Treatment of underlying monoclonal gammopathy of clinical significance (MGCS) with lenalidomide for IVIG-resistant scleromyxedema. Journal Of The American Academy Of Dermatology 2022, 87: ab122. DOI: 10.1016/j.jaad.2022.06.521.
• 660 Epigenetic regulation of Slamf6 expression in the immune response to melanomaMicevic G, Flavell R, Bosenberg M. 660 Epigenetic regulation of Slamf6 expression in the immune response to melanoma. Journal Of Investigative Dermatology 2022, 142: s113. DOI: 10.1016/j.jid.2022.05.1066.
• LB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanomaChang J, Shin K, Lewis J, Suh H, Bosenberg M, Saltzman W, Girardi M. LB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanoma. Journal Of Investigative Dermatology 2022, 142: b29. DOI: 10.1016/j.jid.2022.05.1024.
• 580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignanciesChang J, Suh H, Lewis J, Bosenberg M, Saltzman W, Girardi M. 580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignancies. Journal Of Investigative Dermatology 2022, 142: s99. DOI: 10.1016/j.jid.2022.05.589.
• Abstract 1357: T cell memory and the critical effectors of successful anticancer immune responseDaniels A, Damsky W, McGeary M, Iwasaki A, Bosenberg M. Abstract 1357: T cell memory and the critical effectors of successful anticancer immune response. Cancer Research 2022, 82: 1357-1357. DOI: 10.1158/1538-7445.am2022-1357.
• Abstract 2166: Ibuprofen induces ferroptosis to potentiate antitumor immunityTalty R, Ferreira M, Krykbaeva I, Bosenberg M. Abstract 2166: Ibuprofen induces ferroptosis to potentiate antitumor immunity. Cancer Research 2022, 82: 2166-2166. DOI: 10.1158/1538-7445.am2022-2166.
• Abstract 1380: Setdb1 -loss reactivates ERV expression and interferon signaling to induce immune-mediated melanoma clearanceMcGeary M, Damsky W, Daniels D, Micevic G, Song E, Lou H, Calderwood C, Paradkar S, Iwasaki A, Calderwood D, Turk B, Bosenberg M. Abstract 1380: Setdb1 -loss reactivates ERV expression and interferon signaling to induce immune-mediated melanoma clearance. Cancer Research 2022, 82: 1380-1380. DOI: 10.1158/1538-7445.am2022-1380.
• Abstract 70: Obesity-induced impairment of antitumor immunity is associated with an immunosuppressive tumor immune landscapePazdrak B, Mak D, Damsky W, Bosenberg M, Lochmann B, Gubin M, McQuade J. Abstract 70: Obesity-induced impairment of antitumor immunity is associated with an immunosuppressive tumor immune landscape. Cancer Research 2021, 81: 70-70. DOI: 10.1158/1538-7445.am2021-70.
• Abstract 3424: IL-18 immunotherapy is efficacious against checkpoint-immunotherapy refractory tumors by promoting the maturation of highly proliferative, polyfunctional NK cellsWeizman O, Zhou T, Damsky W, McGeary M, Bosenberg M, Ring A. Abstract 3424: IL-18 immunotherapy is efficacious against checkpoint-immunotherapy refractory tumors by promoting the maturation of highly proliferative, polyfunctional NK cells. Cancer Research 2020, 80: 3424-3424. DOI: 10.1158/1538-7445.am2020-3424.
• Abstract 2156: IL-18 pathway agonism expands intratumoral PD1+ Tcf1+ stem-like CD8+ cells and their polyfunctional effector progeny to promote anti-tumor immunityZhou T, Weizman O, Damsky W, McGeary M, Bosenberg M, Ring A. Abstract 2156: IL-18 pathway agonism expands intratumoral PD1+ Tcf1+ stem-like CD8+ cells and their polyfunctional effector progeny to promote anti-tumor immunity. Cancer Research 2020, 80: 2156-2156. DOI: 10.1158/1538-7445.am2020-2156.
• 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMAOria V, Zhang H, Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. Neuro-Oncology Advances 2020, 2: ii3-ii3. PMCID: PMC7401364, DOI: 10.1093/noajnl/vdaa073.009.
• 668 Ulcerated melanomas exhibit epigenetic changes in epidermal and immune response genesMicevic G, Bosenberg M. 668 Ulcerated melanomas exhibit epigenetic changes in epidermal and immune response genes. Journal Of Investigative Dermatology 2020, 140: s90. DOI: 10.1016/j.jid.2020.03.680.
• IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapyZhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 2020, 583: 609-614. PMID: 32581358, PMCID: PMC7381364, DOI: 10.1038/s41586-020-2422-6.
• LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanomaKrykbaeva I, Damsky W, Turner N, Perry C, Kluger H, Bosenberg M. LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma. Journal Of Investigative Dermatology 2019, 139: b19. DOI: 10.1016/j.jid.2019.06.089.
• 012 Profiling immune cells using tissue cytometry and immune cell clustersBlenman K, Bosenberg M. 012 Profiling immune cells using tissue cytometry and immune cell clusters. Journal Of Investigative Dermatology 2019, 139: s216. DOI: 10.1016/j.jid.2019.07.015.
• Abstract 4622: The YUMMER.G mouse melanoma model recapitulates the heterogeneous response to immune checkpoint blockade based on patient sexRamseier J, Charos A, Park K, Damsky W, Bosenberg M. Abstract 4622: The YUMMER.G mouse melanoma model recapitulates the heterogeneous response to immune checkpoint blockade based on patient sex. Cancer Research 2019, 79: 4622-4622. DOI: 10.1158/1538-7445.am2019-4622.
• Abstract 4622: The YUMMER.G mouse melanoma model recapitulates the heterogeneous response to immune checkpoint blockade based on patient sexRamseier J, Charos A, Park K, Damsky W, Bosenberg M. Abstract 4622: The YUMMER.G mouse melanoma model recapitulates the heterogeneous response to immune checkpoint blockade based on patient sex. 2019, 4622-4622. DOI: 10.1158/1538-7445.sabcs18-4622.
• Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity.Ferreira M, Krykbaeva I, Damsky W, Kluger H, Bosenberg M. Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity. Journal Of Clinical Oncology 2019, 37: e14114-e14114. DOI: 10.1200/jco.2019.37.15_suppl.e14114.
• 789 Immune checkpoint therapy polarizes fibroblasts into a proinflammatory stateRamseier J, Thakral D, Damsky W, Bosenberg M. 789 Immune checkpoint therapy polarizes fibroblasts into a proinflammatory state. Journal Of Investigative Dermatology 2019, 139: s136. DOI: 10.1016/j.jid.2019.03.865.
• 783 Evaluating the impact of high-dose steroids on checkpoint inhibitor efficacy in a murine model of melanomaFerreira M, Damsky W, Bosenberg M. 783 Evaluating the impact of high-dose steroids on checkpoint inhibitor efficacy in a murine model of melanoma. Journal Of Investigative Dermatology 2019, 139: s135. DOI: 10.1016/j.jid.2019.03.859.
• PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survivalMicevic G, Thakral D, McGeary M, Bosenberg M. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell & Melanoma Research 2018, 32: 435-440. PMID: 30343532, PMCID: PMC6475614, DOI: 10.1111/pcmr.12745.
• 1185 DNA hypermethylation of MHC class-I genes is associated with reduced expression and survival in melanomaMicevic G, Thakral D, McGeary M, Bosenberg M. 1185 DNA hypermethylation of MHC class-I genes is associated with reduced expression and survival in melanoma. Journal Of Investigative Dermatology 2018, 138: s201. DOI: 10.1016/j.jid.2018.03.1200.
• 1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma modelTurner N, Damsky W, Wang J, Meeth K, Blenman K, Bosenberg M. 1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma model. Journal Of Investigative Dermatology 2018, 138: s211. DOI: 10.1016/j.jid.2018.03.1260.
• (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma SurvivalMicevic G, Muthusamy V, Pupo G, Scolyer R, Long G, Bosenberg M. (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e9. DOI: 10.1016/j.ijrobp.2017.02.065.
• 791 DNA methyltransferases play important but antagonistic roles in melanoma formation and growthMicevic G, Bosenberg M. 791 DNA methyltransferases play important but antagonistic roles in melanoma formation and growth. Journal Of Investigative Dermatology 2017, 137: s136. DOI: 10.1016/j.jid.2017.02.816.
• 766 Exposure to ultraviolet light enhances anti-tumor immunity and response to immunotherapy in a mouse model of melanomaDamsky W, Wang J, Perry C, Meeth K, Kaech S, Bosenberg M. 766 Exposure to ultraviolet light enhances anti-tumor immunity and response to immunotherapy in a mouse model of melanoma. Journal Of Investigative Dermatology 2017, 137: s132. DOI: 10.1016/j.jid.2017.02.791.
• 789 Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanomaTheodosakis N, Langdon C, Micevic G, Stern D, Bosenberg M. 789 Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma. Journal Of Investigative Dermatology 2017, 137: s136. DOI: 10.1016/j.jid.2017.02.814.
• Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T CellsMoreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research 2016, 4: 845-857. PMID: 27589875, PMCID: PMC5050168, DOI: 10.1158/2326-6066.cir-16-0060.
• 469 Experimental T cells immunotherapy by tumor-loaded ECP-generated dendritic antigen presenting cellsVentura A, Vassall A, Robinson E, Bosenberg M, Bianchi L, Chimenti S, Edelson R. 469 Experimental T cells immunotherapy by tumor-loaded ECP-generated dendritic antigen presenting cells. Journal Of Investigative Dermatology 2016, 136: s240. DOI: 10.1016/j.jid.2016.06.491.
• Abstract 2768: Global DNA hypomethylation is an important feature of melanomaMicevic G, Theodosakis N, Taube J, Bosenberg M, Rodic N. Abstract 2768: Global DNA hypomethylation is an important feature of melanoma. Cancer Research 2016, 76: 2768-2768. DOI: 10.1158/1538-7445.am2016-2768.
• 637 miRNA processing enzyme regulates melanoma formation and growthMicevic G, Meeth K, Theodosakis N, Ventura A, Liu X, Bosenberg M. 637 miRNA processing enzyme regulates melanoma formation and growth. Journal Of Investigative Dermatology 2016, 136: s113. DOI: 10.1016/j.jid.2016.02.678.
• 275 Experimental ECP initiation of selective anti-tumor immunityKhalil D, Ventura A, Vassal A, Han P, Meeth K, Wang J, Filler R, Robinson E, Hanlon D, Bosenberg M, Edelson R. 275 Experimental ECP initiation of selective anti-tumor immunity. Journal Of Investigative Dermatology 2016, 136: s48. DOI: 10.1016/j.jid.2016.02.305.
• 031 Experimental therapeutic melanoma vaccination by ECP-generated dendritic cellsVentura A, Vassal A, Robinson E, Wang J, Meeth K, Bianchi L, Chimenti S, Bosenberg M, Edelson R. 031 Experimental therapeutic melanoma vaccination by ECP-generated dendritic cells. Journal Of Investigative Dermatology 2016, 136: s6. DOI: 10.1016/j.jid.2016.02.055.
• 616 UV-induced somatic mutations elicit a functional T cell response and tumor regression in BRAFV600E, CDKN2A-/-, PTEN-/- melanoma modelWang J, Meeth K, Perry C, Ventura A, Kaech S, Edelson R, Bosenberg M. 616 UV-induced somatic mutations elicit a functional T cell response and tumor regression in BRAFV600E, CDKN2A-/-, PTEN-/- melanoma model. Journal Of Investigative Dermatology 2016, 136: s109. DOI: 10.1016/j.jid.2016.02.656.
• DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTORMicevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports 2016, 14: 2180-2192. PMID: 26923591, PMCID: PMC4785087, DOI: 10.1016/j.celrep.2016.02.010.
• Abstract 5141: A comprehensive system of congenic mouse melanoma models for evaluation of immune therapiesMeeth K, Damsky W, Bosenberg M. Abstract 5141: A comprehensive system of congenic mouse melanoma models for evaluation of immune therapies. 2015, 5141-5141. DOI: 10.1158/1538-7445.am2015-5141.
• Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinomaLangdon C, Wiedemann N, Held M, Platt J, Mamillapalli R, Iyidogan P, Theodosakis N, Levy F, Robichon D, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma. 2015, 2529-2529. DOI: 10.1158/1538-7445.am2015-2529.
• Genomic Classification of Cutaneous MelanomaNetwork T, Akbani R, Akdemir K, Aksoy B, Albert M, Ally A, Amin S, Arachchi H, Arora A, Auman J, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, Bartlett P, Bastian B, Baylin S, Behera M, Belyaev D, Benz C, Bernard B, Beroukhim R, Bir N, Black A, Bodenheimer T, Boice L, Boland G, Bono R, Bootwalla M, Bosenberg M, Bowen J, Bowlby R, Bristow C, Brockway-Lunardi L, Brooks D, Brzezinski J, Bshara W, Buda E, Burns W, Butterfield Y, Button M, Calderone T, Cappellini G, Carter C, Carter S, Cherney L, Cherniack A, Chevalier A, Chin L, Cho J, Cho R, Choi Y, Chu A, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Coons S, Cope L, Crain D, Curley E, Danilova L, D’Atri S, Davidsen T, Davies M, Delman K, Demchok J, Deng Q, Deribe Y, Dhalla N, Dhir R, DiCara D, Dinikin M, Dubina M, Ebrom J, Egea S, Eley G, Engel J, Eschbacher J, Fedosenko K, Felau I, Fennell T, Ferguson M, Fisher S, Flaherty K, Frazer S, Frick J, Fulidou V, Gabriel S, Gao J, Gardner J, Garraway L, Gastier-Foster J, Gaudioso C, Gehlenborg N, Genovese G, Gerken M, Gershenwald J, Getz G, Gomez-Fernandez C, Gribbin T, Grimsby J, Gross B, Guin R, Gutschner T, Hadjipanayis A, Halaban R, Hanf B, Haussler D, Haydu L, Hayes D, Hayward N, Heiman D, Herbert L, Herman J, Hersey P, Hoadley K, Hodis E, Holt R, Hoon D, Hoppough S, Hoyle A, Huang F, Huang M, Huang S, Hutter C, Ibbs M, Iype L, Jacobsen A, Jakrot V, Janning A, Jeck W, Jefferys S, Jensen M, Jones C, Jones S, Ju Z, Kakavand H, Kang H, Kefford R, Khuri F, Kim J, Kirkwood J, Klode J, Korkut A, Korski K, Krauthammer M, Kucherlapati R, Kwong L, Kycler W, Ladanyi M, Lai P, Laird P, Lander E, Lawrence M, Lazar A, Łaźniak R, Lee D, Lee J, Lee J, Lee K, Lee S, Lee W, Leporowska E, Leraas K, Li H, Lichtenberg T, Lichtenstein L, Lin P, Ling S, Liu J, Liu O, Liu W, Long G, Lu Y, Ma, Ma Y, Mackiewicz A, Mahadeshwar H, Malke J, Mallery D, Manikhas G, Mann G, Marra M, Matejka B, Mayo M, Mehrabi S, Meng S, Meyerson M, Mieczkowski P, Miller J, Miller M, Mills G, Moiseenko F, Moore R, Morris S, Morrison C, Morton D, Moschos S, Mose L, Muller F, Mungall A, Murawa D, Murawa P, Murray B, Nezi L, Ng S, Nicholson D, Noble M, Osunkoya A, Owonikoko T, Ozenberger B, Pagani E, Paklina O, Pantazi A, Parfenov M, Parfitt J, Park P, Park W, Parker J, Passarelli F, Penny R, Perou C, Pihl T, Potapova O, Prieto V, Protopopov A, Quinn M, Radenbaugh A, Rai K, Ramalingam S, Raman A, Ramirez N, Ramirez R, Rao U, Rathmell W, Ren X, Reynolds S, Roach J, Robertson A, Ross M, Roszik J, Russo G, Saksena G, Saller C, Samuels Y, Sander C, Sander C, Sandusky G, Santoso N, Saul M, Saw R, Schadendorf D, Schein J, Schultz N, Schumacher S, Schwallier C, Scolyer R, Seidman J, Sekhar P, Sekhon H, Senbabaoglu Y, Seth S, Shannon K, Sharpe S, Sharpless N, Shaw K, Shelton C, Shelton T, Shen R, Sheth M, Shi Y, Shiau C, Shmulevich I, Sica G, Simons J, Sinha R, Sipahimalani P, Sofia H, Soloway M, Song X, Sougnez C, Spillane A, Spychała A, Stretch J, Stuart J, Suchorska W, Sucker A, Sumer S, Sun Y, Synott M, Tabak B, Tabler T, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Tatka H, Taylor B, Teresiak M, Thiessen N, Thompson J, Thorne L, Thorsson V, Trent J, Triche T, Tsai K, Tsou P, Van Den Berg D, Van Allen E, Veluvolu U, Verhaak R, Voet D, Voronina O, Walter V, Walton J, Wan Y, Wang Y, Wang Z, Waring S, Watson I, Weinhold N, Weinstein J, Weisenberger D, White P, Wilkerson M, Wilmott J, Wise L, Wiznerowicz M, Woodman S, Wu C, Wu C, Wu J, Wu Y, Xi R, Xu A, Yang D, Yang L, Yang L, Zack T, Zenklusen J, Zhang H, Zhang J, Zhang W, Zhao X, Zhu J, Zhu K, Zimmer L, Zmuda E, Zou L. Genomic Classification of Cutaneous Melanoma. Cell 2015, 161: 1681-1696. PMID: 26091043, PMCID: PMC4580370, DOI: 10.1016/j.cell.2015.05.044.
• mTORC1 Activation Blocks Braf V600E -Induced Growth Arrest but Is Insufficient for Melanoma FormationDamsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 Activation Blocks Braf V600E -Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell 2015, 27: 41-56. PMID: 25584893, PMCID: PMC4295062, DOI: 10.1016/j.ccell.2014.11.014.
• Abstract 59: PDK1 in melanoma development and metastasisScortegagna M, Ruller C, Feng Y, Lazova R, Kluger H, Li J, De S, Rickert R, Pellecchia M, Bosenberg M, Ronai Z. Abstract 59: PDK1 in melanoma development and metastasis. 2014, 59-59. DOI: 10.1158/1538-7445.am2014-59.
• Abstract 4520: Inhibition of melanoma growth by small molecules that attenuate PI3K/PDK1 signaling and promote ATF2 mitochondrial localizationVarsano T, Feng Y, Claps G, Scortegagna M, Lau E, Leonard M, Pinkerton A, Pellecchia M, Davies M, Bosenberg M, Ronai Z. Abstract 4520: Inhibition of melanoma growth by small molecules that attenuate PI3K/PDK1 signaling and promote ATF2 mitochondrial localization. 2014, 4520-4520. DOI: 10.1158/1538-7445.am2014-4520.
• Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer modelsLangdon C, Wiedemann N, Held M, Platt J, Lévy F, Robichon D, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models. 2014, 5441-5441. DOI: 10.1158/1538-7445.am2014-5441.
• Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancerLangdon C, Wiedemann N, Hajjami H, Held M, Platt J, Vuagniaux G, Bosenberg M, Stern D, Lévy F. Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer. 2014, 1792-1792. DOI: 10.1158/1538-7445.am2014-1792.
• Imaging and Treating Tumors by Targeting their Acidity with Phlip, a Ph-Sensitve Insertion PeptideEngelman D, An M, Andreev O, Barrera F, Bahal R, Bosenberg M, Cheng C, Glazer P, Karabadzhak A, Reshetnyak Y, Saltzman W, Slack F, Svoronos A, Thevenin D. Imaging and Treating Tumors by Targeting their Acidity with Phlip, a Ph-Sensitve Insertion Peptide. Biophysical Journal 2014, 106: 231a. DOI: 10.1016/j.bpj.2013.11.1350.
• Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells.Langdon C, Wiedemann N, Held M, Platt J, Lévy F, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells. Molecular Cancer Therapeutics 2013, 12: a16-a16. DOI: 10.1158/1535-7163.targ-13-a16.
• Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma.McMahon M, Das Thakur M, Marsh V, Silva J, Landman A, Deuker M, Salangsang F, Pryer N, Phillips W, Levesque M, Dummer R, Bosenberg M, Sellers W, Stuart D. Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma. Cancer Research 2013, 73: sy17-03-sy17-03. DOI: 10.1158/1538-7445.am2013-sy17-03.
• Abstract 1116: Sleeping Beauty mutagenesis identifies genes and pathways that cooperate with BrafV600E in melanoma initiation and progression.Mann M, Black M, Ward J, Bosenberg M, McMahon M, Print C, Adams D, Copeland N, Jenkins N. Abstract 1116: Sleeping Beauty mutagenesis identifies genes and pathways that cooperate with BrafV600E in melanoma initiation and progression. Cancer Research 2013, 73: 1116-1116. DOI: 10.1158/1538-7445.am2013-1116.
• Abstract 1534: CD163-expressing macrophages constitute a distinct malignancy-promoting phenotype in melanoma facilitating tumor development, progression, and metastasis: Implications for novel anticancer therapy.Maniecki M, Etzerodt A, Damsky W, Rafique A, Gonzalez D, Dyrskjøt L, Møller H, Bosenberg M, Moestrup S. Abstract 1534: CD163-expressing macrophages constitute a distinct malignancy-promoting phenotype in melanoma facilitating tumor development, progression, and metastasis: Implications for novel anticancer therapy. Cancer Research 2013, 73: 1534-1534. DOI: 10.1158/1538-7445.am2013-1534.
• Targeting of Melanoma by pH (Low) Insertion Peptide (pHLIP)Svoronos A, Cheng C, Barrera F, Saltzman W, Bosenberg M, Engelman D. Targeting of Melanoma by pH (Low) Insertion Peptide (pHLIP). Biophysical Journal 2013, 104: 677a. DOI: 10.1016/j.bpj.2012.11.3740.
• Abstract 2822: Characterization of the effects of PLX4720 in the immunocompetent BRAF/PTEN mouse melanoma modelMarzuka A, Bosenberg M. Abstract 2822: Characterization of the effects of PLX4720 in the immunocompetent BRAF/PTEN mouse melanoma model. Cancer Research 2012, 72: 2822-2822. DOI: 10.1158/1538-7445.am2012-2822.
• β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient MelanomasDamsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Rothberg B, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 2011, 20: 741-754. PMID: 22172720, PMCID: PMC3241928, DOI: 10.1016/j.ccr.2011.10.030.
• Proinvasion Metastasis Drivers in Early-Stage Melanoma Are OncogenesScott K, Nogueira C, Heffernan T, van Doorn R, Dhakal S, Hanna J, Min C, Jaskelioff M, Xiao Y, Wu C, Cameron L, Perry S, Zeid R, Feinberg T, Kim M, Woude G, Granter S, Bosenberg M, Chu G, DePinho R, Rimm D, Chin L. Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes. Cancer Cell 2011, 20: 277. DOI: 10.1016/j.ccr.2011.08.005.
• Abstract 539: The expression of monocyte/macrophage-restricted scavenger receptor CD163 by malignant cells may be a consequence of cell fusion with tumor-associated macrophages: A novel target for cancer therapyManiecki M, Damsky W, Ulhøi B, Steiniche T, Ørntoft T, Dyrskjøt L, Borre M, Kjeldsen E, Bosenberg M, Møller H. Abstract 539: The expression of monocyte/macrophage-restricted scavenger receptor CD163 by malignant cells may be a consequence of cell fusion with tumor-associated macrophages: A novel target for cancer therapy. Cancer Research 2011, 71: 539-539. DOI: 10.1158/1538-7445.am2011-539.
• Abstract 3377: The effect of E-cadherin loss on melanoma formation and metastasis in a conditional mouse modelRosenbaum L, Damsky W, Bosenberg M. Abstract 3377: The effect of E-cadherin loss on melanoma formation and metastasis in a conditional mouse model. Cancer Research 2011, 71: 3377-3377. DOI: 10.1158/1538-7445.am2011-3377.
• Genetic alterations in malignant melanomaHeld M, Bosenberg M. Genetic alterations in malignant melanoma. Diagnostic Histopathology 2010, 16: 317-320. DOI: 10.1016/j.mpdhp.2010.03.001.
• Abstract LB-154: Loss of PTEN cooperates with activated RAS in melanoma genesis and progressionNogueira C, Kim K, Paraiso K, Dannenberg J, Bosenberg M, Chin L, Kim M. Abstract LB-154: Loss of PTEN cooperates with activated RAS in melanoma genesis and progression. Cancer Research 2010, 70: lb-154-lb-154. DOI: 10.1158/1538-7445.am10-lb-154.
• BrafV600E cooperates with Pten loss to induce metastatic melanomaDankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr W, You MJ, DePinho RA, McMahon M, Bosenberg M. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009, 41: 544-552. PMID: 19282848, PMCID: PMC2705918, DOI: 10.1038/ng.356.
• A Painful Cutaneous Nodule on the Forearm of an Immunocompromised PatientPritt B, Bosenberg M, Winn W. A Painful Cutaneous Nodule on the Forearm of an Immunocompromised Patient. Lab Medicine 2006, 37: 343-345. DOI: 10.1309/3wwdwn7ar9fccce1.
• Skin CancerBosenberg M. Skin Cancer. 2004 DOI: 10.1002/0471675067.mmc009.
• Telomere dysfunction and evolution of intestinal carcinoma in mice and humansRudolph K, Millard M, Bosenberg M, DePinho R. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nature Genetics 2001, 28: 155-159. PMID: 11381263, DOI: 10.1038/88871.
• Juxtacrine cell signaling moleculesBosenberg M, Massagué J. Juxtacrine cell signaling molecules. Current Opinion In Cell Biology 1993, 5: 832-838. PMID: 7694603, DOI: 10.1016/0955-0674(93)90032-l.
• Activated release of membrane-anchored TGF-alpha in the absence of cytosolBosenberg M, Pandiella A, Massagué J. Activated release of membrane-anchored TGF-alpha in the absence of cytosol. Journal Of Cell Biology 1993, 122: 95-101. PMID: 8314849, PMCID: PMC2119606, DOI: 10.1083/jcb.122.1.95.
• The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFα into soluble growth factorBosenberg M, Pandiella A, Massagué J. The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFα into soluble growth factor. Cell 1992, 71: 1157-1165. PMID: 1473151, DOI: 10.1016/s0092-8674(05)80064-9.